To ask the Secretary of State for Health and Social Care, what steps his Department (a) is taking to improve access to medicinal cannabis for people living with multiple sclerosis and (b) if he will publish a Government strategy for improving access to medicinal cannabis.
Two prescription medicines - Sativex – for the treatment of spasticity in Multiple Sclerosis patients, and Epidyolex – for the treatment of seizures associated with two rare forms of epilepsy, have been made available for prescribing on the National Health Service, where clinically appropriate. This follows clear demonstrated evidence of their safety, and clinical and cost effectiveness.
We continue to work hard with the health system, industry and researchers to improve the evidence base for other cannabis-based medicines, and to implement the recommendations of NHS England and NHS Improvement’s review on barriers to accessing unlicensed cannabis based medicinal products. This includes the design of clinical trials and the establishment of a national patient registry.